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ABSTRACT
Ovarian cancer is the most deadly gynecological malignancy since most patients 
have metastatic disease at the time of diagnosis. Therefore, identification of critical 
pathways that contribute to ovarian cancer progression is necessary to yield novel 
therapeutic targets. Recently we reported that the DNA binding protein ARID3B is 
overexpressed in human ovarian tumors. To determine if ARID3B has oncogenic 
functions in vivo, ovarian cancer cell lines stably expressing ARID3B were injected 
intraperitoneally into nude mice. Overexpression of ARID3B increased tumor burden 
and decreased survival. To assess how ARID3B contributes to the increased tumor 
growth in vivo, we identified ARID3B induced genes in tumor ascites cells. ARID3B 
induced expression of genes associated with metastasis and cancer stem cells (CD44, 
LGR5, PROM1 (CD133), and Notch2). Moreover, ARID3B increased the number of 
CD133+ (a cancer stem cell marker) cells compared to control cells. The increase 
in CD133+ cells resulting from ARID3B expression was accompanied by enhanced 
paclitaxel resistance. Our data demonstrate that ARID3B boosts production of CD133+ 
cells and increases ovarian cancer progression in vivo.
INTRODUCTION
Ovarian cancer is the leading cause of death from 
a gynecological malignancy and resulted in an estimated 
14,030 deaths in 2013 (American Cancer Society Facts 
and Figures 2013). Patients initially respond well to 
chemotherapy, but most patients will relapse after the 
initial platinum/taxane therapy [1]. Understanding the 
molecular mechanisms that drive malignancy is critical 
for diagnosing and developing effective treatments for this 
devastating disease. 
Data indicate that cancer stem cells (CSC) contribute 
to chemoresistance. CSCs are a subset of slow cycling 
and undifferentiated cells that divide asymmetrically to 
generate highly proliferative, invasive, and chemoresistant 
tumor cells [2]. Following chemotherapy, the CSCs 
survive and proliferate generating chemoresistant 
tumors. CSCs have been isolated by a number of groups 
from malignant ascites from ovarian cancer patients [3-
11]. These cells express canonical stem cell markers, 
are chemoresistant, and tumorigenic. One of the most 
commonly reported CSC markers is CD133. CD133 
expression is low in normal ovary and benign tumors 
compared to malignant ovarian cancer [12]. Furthermore 
CD133+ cells are more tumorigenic than CD133- cells, 
suggesting that the CD133 population has stem cell 
properties [13].
Recently we reported that the transcription factor 
ARID3B, a member of the AT-rich interactive (ARID) 
family [14], is overexpressed in serous ovarian cancer 
[15]. In addition to being overexpressed in ovarian cancer 
and late stage neuroblastoma [16], ARID3B is highly 
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expressed in embryonic (ES) and induced pluripotent 
stem cells [17, 18]. In ES cells ARID3B interacts with 
the stem cell factors Oct4 and Nanog [18]. Therefore we 
hypothesized that ARID3B may contribute to ovarian 
cancer growth by impacting cancer stem cell development. 
To address this hypothesis, we assessed the role of 
ARID3B in ovarian tumor growth and determined the 
effects of ARID3B overexpression on gene expression and 
drug resistance. We generated a xenograft mouse model 
of ovarian cancer that recapitulates the level of ARID3B 
overexpression found in human tumor sections. We found 
that ARID3B increases tumor growth in vivo and induces 
CSC genes in tumor ascites. Furthermore, ARID3B 
overexpression increases the pool of CD133+ spheroids 
in ovarian cancer cell lines. This study demonstrates 
for the first time that ARID3B promotes ovarian tumor 
development in part by regulating stem cell genes.
RESULTS
Generation of xenograft mouse model of ARID3B 
overexpression in SKOV3IP ovarian cancer cells
Recently we demonstrated that ARID3B is 
significantly overexpressed in ovarian cancer compared 
to normal ovarian surface epithelium and benign ovarian 
tumors [19]. We wanted to establish a xenograft model 
of ovarian cancer in mice where ARID3B is expressed 
at comparable levels to what is observed in human 
tumors. To do this we analyzed the expression levels 
of ARID3B in human ovarian cancer by performing 
immunohistochemistry (IHC) for ARID3B on ovarian 
cancer tissue microarrays (TMAs). The TMAs contained 
duplicate samples from 102 different patients of which 45 
were serous. Unlike our previous TMA analysis that was 
performed on commercially available TMAs, this TMA 
data set had patient outcome with regards to tumor relapse, 
survival, and time until survival. Using Aperio software, 
we were able to blindly quantify the percentage of cells 
with low, moderate, and high nuclear or cytoplasmic 
staining. In order to rule out background staining, we only 
further analyzed moderate and high staining (Figure 1A). 
We found that out of 102 patients, 60 had moderate nuclear 
ARID3B and relapsed; this correlation was significant 
(p=0.025, t-test). Interestingly strong nuclear staining 
did not correlate with relapse (p=0.15). We also found 
that moderate nuclear ARID3B correlated significantly 
with decreased time until relapse (p=0.029). We found no 
correlation between ARID3B and stage, histological type, 
or survival.
To recapitulate the overexpression of nuclear 
ARID3B found in the human tumors we generated 
xenografts in nude mice with ARID3B overexpressing 
SKOV3IP cells. Refer to the nuclear expression of 
ARID3B in Fig. 1. The SKOV3IP cell line is derived 
from ascites cells that developed in a mouse injected 
intraperitoneally (IP) with SKOV3 cells [20]. In a pilot 
study, we transduced SKOV3IP cells with lentivirus 
containing red fluorescent protein (RFP) or each of the 
two ARID3B splice forms. ARID3B has an alternative 
Figure 1: SKOV3IP xenograft tumors recapitulate the expression of ARID3B in ovarian cancer. (A) Immunohistochemistry 
was performed on tissue microarrays containing 102 cases of ovarian cancer. TMAs were scored for ARID3B expression. Representative 
images of light staining for ARID3B staining: (clear cell carcinoma, grade 2, stage IIC), moderate (serous, grade 3, stage IIIC), or strong 
(serous, grade3, stage IV). Black arrow indicates nucleus. Original magnification is 20x. (B) IHC was performed on xenografts in nude 
mice from SKOV3IP-RFP, SKOV3-ARID3BSH, and SKOV3IP-ARID3BFL cells. 
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splice form, ARID3BSH. Since it lacks 81% of the DNA 
binding domain [15] it was included in our analysis as a 
negative control. These cells are referred to as SKOV3IP-
RFP, SKOV3IP-ARID3BFL, and SKOV3IP-ARID3BSH. 
Cells from each cohort were injected IP into nude mice 
and were allowed to grow for 3 weeks. By 3 weeks 
the SKOV3IP-ARID3BFL cells formed large tumors, 
mice were euthanized, and tumors were fixed. IHC was 
performed to compare the expression of ARID3B in 
SKOV3IP-ARID3BFL tumors to human tumors. This 
analysis showed that the level of nuclear ARID3B in 
SKOV3IP-ARID3BFL tumors was similar to what was 
observed in 88% of human ovarian tumors (Figure 1A 
and B). The SKOV3IP-ARID3B xenograft tumors mimic 
the overexpression of ARID3B found in human ovarian 
cancer.
ARID3BFL increases tumor burden in vivo
In our initial xenograft study we observed that 
ARID3BFL expressing tumors were considerably larger 
than the controls. We therefore repeated this study to 
determine how ARID3B influenced tumor growth, 
survival, and gene expression. We performed 2 separate 
experiments using cells that were transduced with RFP 
or ARID3B. Western blot of the SKOV3IP cells in both 
experiments is in shown in Figure 2A (compare parental 
and RFP controls in lanes 4-6 to SKOV3IP-ARID3BFL 
cells in lanes 7 and 8). Female nude (nu/nu) mice were IP 
injected with 106 SKOV3IP-RFP, SKOV3IP-ARID3BFL, 
or SKOV3IP-ARID3BSH cells. Beginning 10 days after 
IP injection of the SKOV3IP tumor cells, fluorescent in 
vivo imaging of tumor growth was conducted weekly. A 
representative image of four mice from each of the three 
groups at 31 days post injection (Figure 2B) demonstrates 
that the mice injected with SKOV3IP-ARID3BFL cells 
developed large tumors earlier than the mice injected 
with SKOV3IP-RFP or SKOV3IP-ARID3BSH cells. A 
montage of images of representative mice between 18-39d 
(when all the SKOV3IP-ARID3BFL injected mice had 
died) is shown in Supplemental Figure 1. In contrast to the 
SKOV3IP-RFP and SKOV3IP-ARID3BSH injected mice, 
SKOV3IP-ARID3BFL mice also frequently presented 
with distended abdomens with large tumors visible 
beneath the skin (Figure 2C). 
Mice were euthanized when they progressed to 
the point where the tumors were very large. Then the 
tumors were isolated and dissected from the organs. 
Figure 2D shows the representative tumor burden from 
each group of mice. Quantification of tumor weight 
revealed that the SKOV3IP-ARID3BFL tumors were 
on average more than 2.5x larger than those collected 
from the SKOV3IP-RFP mice. The average weights 
of the tumors were 1.91g+/-0.33 for SKOV3IP-RFP 
tumors, 3.22g+/-0.47 for SKOV3IP ARID3BSH tumors, 
and 5.46g+/-0.49 for SKOV3IP-ARID3BFL tumors 
(Supplemental Table 1). Survival analysis showed that 
the median survival for SKOV3IP-ARID3BFL tumor 
bearing mice was significantly reduced compared to mice 
bearing SKOV3IP-RFP or SKOV3IP-ARID3BSH tumors 
(RFP=51 days, ARID3BSH=52 days, ARID3BFL=36 
days; P=0.0074) (Figure 2E). Collectively, these data 
demonstrate that overexpression of ARID3BFL results in 
a more aggressive ovarian cancer phenotype in vivo.
ARID3B increases cell adhesion but not 
proliferation or invasion 
We wanted to define the mechanisms by which 
ARID3B increases tumorigenesis. We performed IHC 
analysis for proliferation marker Ki67 and apoptosis 
marker cleaved Parp1 (Supplemental Figure 2) on RFP 
and ARID3BFL tumors. We did not find any difference in 
Ki67 staining. We actually detected more cleaved Parp1 
in the ARID3B overexpressing tumors. We believe this 
was a due to the tumors being quite large and having 
large avascular regions. We counted the number of blood 
vessels in sections of SKOV3IP-RFP and SKOV3IP-
ARID3BFL xenografts and found no statistical difference 
between the two. These data suggest that the increase in 
tumor burden resulting from ARID3B expression is not 
increased proliferation or decreased apoptosis. 
We next assessed if ARID3B enhances tumor 
development in vivo by altering cells intrinsic phenotypes. 
We analyzed SKOV3 and SKOV3IP parental, RFP, 
ARID3BFL, and ARID3BSH expressing cells for 
changes in proliferation and invasion. We discovered that 
ARID3BFL and ARID3BSH did not affect proliferation 
(Supplemental Figure 3A, B) or invasion in vitro 
(Supplemental Figure 3C, D). We found that the cells 
expressing ARID3BFL had increased cellular projections 
and altered actin organization (Supplemental Figure 
4A. B). Furthermore, ARID3BFL but not ARID3BSH 
increased adhesion to a wide range of extracellular 
matrix proteins (Supplemental Figure 4C) and increased 
vitronectin haptotaxis (Supplemental Figure 4D). The 
results indicate that ARID3B alters cell-matrix adhesion, 
which may contribute to increased tumor growth in vivo.
ARID3B induces expression of cancer stem cell 
associated genes 
ARID3B is a DNA binding protein [14, 21], 
however how ARID3B regulates tumor pathways has not 
been investigated. Therefore, we performed a microarray 
to identify putative ARID3B regulated genes that are 
induced by ARID3B in our tumor model. For this study 
RNA was isolated from ascites cells present in the mouse 
xenografts. We chose to use these cells because ascites 
fluid contains CSCs, which contribute to aggressive tumor 
behavior and because ARID3B is found in stem cell 
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Figure 2: ARID3BFL accelerates tumor growth and decreases survival. (A) Representative western blot was performed for 
ARID3BFL and Histone H3 in SKOV3 or SKOV3IP parental cells (lanes 1 and 4), RFP control cells (lanes 2, 5, and 6), and cells stably 
expressing ARID3BFL (lanes 3, 7 and 8). Densitometry (fold-change) is indicated under lanes. (B) Live in vivo fluorescent imaging of 
mice injected with SKOV3IP-RFP, SKOV3IP-ARID3BSH, or SKOV3IP-ARID3BFL cells. The live fluorescent images were obtained 31d 
post IP injection via the Kodak Multispectral FX. (C) Digital photographs of representative mice bearing xenograft tumors (SKOV3IP-
RFP, SKOV3IP-ARID3BFL, and SKOV3IP-ARID3BSH) were taken. (D) Representative SKOV3IP-RFP, SKOV3IP-ARID3BFL, and 
SKOV3IP-ARID3BSH xenograft tumors. (E) Kaplan-Meier curve demonstrating that the median survival for SKOV3IP-ARID3BFL tumor 
bearing mice is significantly shorter (36 days) than SKOV3IP-RFP tumor (51 days), and SKOV3IP-ARID3BSH (52 days) (P=0.0074). 
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populations [3-11]. Isolated ascites cells were subsequently 
cultured ex vivo to remove non-tumor cells. We confirmed 
that the ex vivo cultures contained only SKOV3IP-RFP 
or SKOV3IP-ARID3BFL cells by examining the cells for 
RFP expression via fluorescent microscopy. Microarray 
was performed on RNA isolated from ascites cells from 
three independent SKOV3IP-RFP injected mice and three 
independent SKOV3IP-ARID3BFL injected mice. The top 
35 upregulated genes in the SKOV3IP-ARID3BFL ascites 
are shown in Supplemental Table 2. Pathway analysis 
using Ingenuity Systems IPA software demonstrates that 
the top three biological functions that are associated with 
ARID3BFL induced genes are Cell Death and Survival, 
Cellular Movement, and Cancer. We used qRT-PCR 
to confirm that two of the most highly induced genes 
COL1A1 and COL1A2 were indeed induced in our ascites 
samples from SKOV3IP-ARID3BFL tumors compared 
to the RFP tumors (Figure 3 A and B). Alterations in 
the expression of collagen genes are associated with 
metastasis in ovarian cancer [22]. Importantly COL1A1 
is both associated with CSCs and contributes to ovarian 
cancer chemoresistance [23, 24]. COL1A2 exhibits altered 
expression in several tumor types most notably gastric 
cancer [25]. Interestingly, 6 of the top 35 genes have 
been implicated in CSCs (supplemental table 2). Table 1 
lists ARID3B induced CSC genes including ST3GAL6, 
ADAM19, and HTATIP2, which were shown to be part of 
Table 1: Cancer stem cell genes induced 
by ARID3B in xenograft tumor ascites
Gene Symbol Fold Change (microarray)
COLA1A 87.13
WISP1 46.6
PROM2 18.75
FN1 16.51
CA9 8.92
SFRP1 8.61
SOX9 7.91
SNAI2 6.66
ADAM19 6.21
ST3GAL6 4.35
CD44 3.84
LIF 3.19
HTATIP2 2.48
SMAD3 2.3
NOTCH2 1.85
Figure 3: ARID3B induces collagen and cancer stem cell genes. qRT-PCR was performed on ascites cells and peritoneal washes 
obtained from SKOV3IP-RFP (N=6) and SKOV3IP-ARID3BFL (N=13) mouse ascites. (A) COL1A1, (B) COL1A2, (C) WISP1, (D) 
LGFR5, (E) SFRP1, and (F) SNAI2 were all significantly increased in ascites derived from SKOV3IP-ARDI3BFL cells compared to 
SKOV3IP-RFP derived ascites. qRT-PCR was performed on OVCA429-RFP and OVCA429-ARDI3BFL cells for (G) WISP1 and (H) 
SFRP1. (* P ≤ 0.05) (** P ≤ 0.01) (*** P ≤ 0.001)
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the CSC signature found in serous ovarian cancer ascites 
[10]. To validate these findings qRT-PCR was performed 
for WISP1, LGR5, SFRP1, and SNAI2, which are in the 
Wnt signaling pathway that is implicated in CSCs [26, 
27] and metastasis [28]. Expression of these genes was 
significantly increased in the ARID3BFL expressing tumor 
cells (Figure 3C-F). To determine whether ARID3BFL 
overexpression regulates these genes in other ovarian 
cancer cell lines, we performed qRT-PCR for SFRP1 
and WISP1 on OVCA429 cells transduced with RFP or 
ARID3B. Expression of ARID3B in OVCA429 cells is 
shown in Supplemental Figure 5. As anticipated, ARID3B 
overexpressing OVCA429 cells exhibited significantly 
increased SFRP1 and WISP1 expression (Figure 3G and 
H). These data suggest that ARID3BFL regulates genes 
involved in CSC gene signature.
ARID3B increases the expression of cancer stem 
cell markers
The finding that ARID3B regulates stem cell 
associated genes is particularly intriguing as ARID3B is 
expressed in ES cells in a protein complex with the stem 
cell transcription factors Nanog, Oct4 and Nac1[18]. Since 
ARID3B is expressed in stem cells and associates with 
stem cell factors, we hypothesized that ARID3B promotes 
tumor growth through the regulation of a CSC phenotype. 
To determine if ARID3BFL increases production of CSCs, 
Figure 4: ARID3BFL expands the pool of ovarian cancer stem cells. (A) Flow cytometry analysis of cell surface expression of 
CD44 and CD133 demonstrates an increase in CD44+/CD133+ cells in the SKOV3IP-ARID3BFL (N=5) cells compared to SKOV3IP (N=3) 
or SKOV3IP-RFP (N=3) cell populations. (SKOV3IP vs. SKOV3IP-ARID3BFL P=0.0037; SKOV3IP-RFP vs. SKOV3IP-ARID3BFL 
P=0.0097). Percentage of cells in each quadrant is indicated on scatter plots. (B) Graph indicating the increase in the percentage of CD44+/
CD133+ cells found in SKOV3IP-ARID3BFL cells. SKOV3IP-ARID3BFL cells had an 82% and 69% increase in CD44+CD133+ over 
SKOV3IP and SKOV3IP-RFP cells respectively. (C) qRT-PCR performed on SKOV3IP-RFP, SKOV3IP-ARID3BFL, and SKOV3IP-
ARID3BSH ascites cells show that PROM1 is significantly increased in SKOV3IP-ARID3BFL (N=11) cells with a 27-fold increase over 
both SKOV3IP-RFP (N=5) and SKOV3IP-ARID3BSH (N=12) cells. (D) qRT-PCR was performed on OVCA429-RFP and OVCA429-
ARDI3BFL cells for PROM1. (E) SKOV3, SKOV3-RFP, and SKOV3-ARID3BFL cells were treated with increasing concentrations of 
paclitaxel. MTT assays were performed to measure viability after 48h. The data were analyzed using a Two-way ANOVA.  (* P ≤ 0.05) (** 
P ≤ 0.01) (*** P ≤ 0.001)
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the cells that were injected into the nude mice to generate 
xenografts and the parental cells (SKOV3IP, SKOV3IP-
RFP and SKOV3IP-ARID3BFL) cells were examined 
for the expression of the stem cell markers CD44 and 
CD133 using flow cytometry [29, 30]. Flow cytometry 
scatter plots in Figure 4A demonstrate the percentage of 
CD44+ (Y-axis) and CD133+ cells (X-axis). This analysis 
revealed that the cell populations expressing both CD44 
and CD133 (PROM1) are significantly increased in the 
SKOV3IP-ARID3BFL cells (Figure 4A and B), suggesting 
that ARID3B increases the population of cells that express 
CD133 and therefore may be CSCs. In addition, qRT-PCR 
for PROM1 demonstrated increased expression (p<0.001) 
in the cells from SKOV3IP-ARID3BFL ascites cells 
compared to SKOV3IP-RFP and SKOV3IP-ARID3BSH 
ascites cells (Figure 4C). Furthermore, ARID3BFL also 
increased PROM1 gene expression in OVCA429 cells 
(Figure 4D). Thus these data suggest that ARID3B 
increases the population of CD133+ cells, that have been 
previously demonstrated to have enhanced tumorigenic 
capabilities[13].
Next, because CD133+ cells are associated with 
chemoresistance we ascertained the impact of ARID3B on 
drug resistance [7, 30, 31]. We chose to evaluate the effects 
of ARID3BFL overexpression on sensitivity to paclitaxel, 
which is used in first-line chemotherapy for ovarian 
cancer and SKOV3 cells already display resistance to 
cisplatin (the other drug used in first-line chemotherapy). 
ARID3BFL overexpressing cells showed a significant 
increase in viability compared to parental and RFP 
control cells when treated with 0.01-100µM paclitaxel 
for 48h (Figure 4E). We also evaluated cell for response 
to cisplatin and found no difference between parental, 
RFP, and ARID3B expressing cells (Supplemental Figure 
6). Therefore, ARID3B overexpression enhances drug 
resistance, which is a well-known property of CSCs.
Lastly we assessed if ARID3B overexpression 
facilitates expansion of spheroids expressing stem 
cell markers using our modification of a published 
protocol [32], which is in press at Journal of Visualized 
Experiments (Cole, et al). We selected for chemoresistant 
ovarian cancer spheroids by culturing cells in cisplatin and 
subsequently culturing the non-adherent cells in a stem 
cell media. Viable spheroids expressed elevated CD133 
(Figure 5). Exogenous ARID3B expression significantly 
increased the expression of PROM1 in CSCs compared 
to non-CSCs as well as parental and RFP control CSCs 
(Figure 5A). ARID3B expression was associated with 
an increase in the percentage of CD117+/CD133+ CSCs 
in SKOV3 CSC cultures (Figure 5B). These studies 
indicate that ARID3B may contribute to ovarian cancer 
tumorigenesis and therapeutic resistance by regulating 
CSC production or function.
DISCUSSION
We previously demonstrated that ARID3B is 
overexpressed in human serous ovarian cancer [19]. 
Figure 5: ARID3B enhances cancer stem cell selection in sphere-cultures. (A) SKOV3, SKOV3-RFP, and SKOV3-ARID3BFL 
cells were enriched for CSCs by selection in cisplatin. qRT-PCR was performed for ARID3B, OCT4, and Prom1 on SKOV3, SKOV3-RFP, 
and SKOV3-ARID3BFL and CSCs isolated from each respective cell line. (B) Flow cytometry was performed for the stem cell markers 
CD117 and CD133 on Control Cells (not selected with cisplatin for CSCs) and CSCs (SKOV3 Parental), SKOV3-RFP (RFP), and SKOV3-
ARID3BFL (ARID3B)). The percentage of CD117+ cells (Y-axis) and CD133+ cells (X-axis) is indicated for each quadrant. (* P ≤ 0.05) 
(** P ≤ 0.01) (*** P ≤ 0.001)
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However, it was not known if ARID3B expression might 
enhance ovarian cancer tumorgenicity as it does for 
neuroblastoma [16]. To address the role of ARID3B in 
ovarian tumorigenesis, we performed mouse xenograft 
assays using SKOV3IP cells expressing exogenous 
ARID3BFL at levels similar to what is observed with IHC 
in human cancer. Our data demonstrates for the first time 
that ARID3B increases ovarian cancer tumor growth in 
a xenograft model of ovarian cancer. Mice injected with 
SKOV3IP-ARID3BFL cells have significantly more 
tumor burden and decreased survival compared to those 
injected with SKOV3IP-RFP or SKOV3IP-ARID3BSH 
cells. Although, the xenografts were only performed using 
SKOV3IP cells, we have found that ARID3B regulates 
CSC genes in OVCA429 cells. Additionally, we found 
that A2780 cells that expressed ARID3BFL formed 
subcutaneous tumors (4/5 mice) more efficiently than 
ones expressing RFP alone (1/5 mice). Future studies of 
ARID3B regulation of tumorigenesis and gene regulation 
in HGSOC cell lines are ongoing and will enable us to 
better dissect the contribution of ARID3B to ovarian 
cancer. 
Many of the mice bearing SKOV3IP-ARID3BFL 
xenografts developed distended abdomens filled with 
ascites. Because ascites are a rich source of CSCs and 
ARID3B had previously been implicated in stem cell 
function[18], we explored the possibility that ARID3B 
increases CSC production. Microarray analysis on ascites 
cells from SKOV3IP-RFP or SKOV3IP-ARID3BFL 
xenografts identified that ARID3B overexpression is 
associated with elevated expression of many stem cell 
markers and metastasis associated genes. We observed 
up-regulation of genes in the Wnt signaling pathway 
(LGR5, SFRP1, and WISP1), which is associated with 
CSCs [27, 30, 33]. Similarly ARID3B overexpressing 
cells exhibited increased expression of genes (ST3GAL6, 
ADAM19, and HTATIP2) reported to be part of the serous 
ovarian cancer ascites CSC signature [10]. The increase in 
CSCs in culture corresponded to an increase in paclitaxel 
resistance. This is particularly interesting since CD133 
is significantly elevated in recurrent platinum-resistant 
tumors [30]. Our results suggest that overexpression of 
ARID3BFL increases the percentage of tumor cells that 
posses “stem like” qualities and this leads to resistance to 
paclitaxel therapy.
Since ARID3B is a DNA binding protein, we 
predict that some of the phenotypes that are attributed to 
ARID3B expression and activation are through its ability 
to directly and indirectly regulate gene transcription. 
Ongoing studies will determine which stem cell genes 
are directly regulated by ARID3B promoter association. 
Interestingly, with ARID3B overexpression we see a 
substantial increase in CD133 mRNA; however, while 
we only observe a small yet significant increase in 
CD133+ (cell surface) cells (from 0.2-1.25%). More 
cells are expressing CD133 mRNA than have the “stem-
cell phenotype”. This suggests that the CD133 mRNA 
may not be translated or transported to the cell surface, 
the reason for this is not known. The role of CD133 in 
stem cell production or function is not clear and warrants 
future investigations. Alternatively, ARID3B may activate 
a stem cell program, but progeny cells further divide and 
“differentiate” or lose their stem cell markers. This may 
impart explain the heterogeneity in the tumor population. 
Therefore ARID3B induces stem cell genes, which may 
contribute to the increased tumor production in xenografts 
expressing ARID3BFL.
We found that moderate, but not high expression 
of ARID3B in the nucleus significantly correlates with 
ovarian cancer relapse. This agrees with our published data 
demonstrating that exceedingly high levels of ARID3B 
lead to TNF-mediated apoptosis [15]. In contrast, more 
moderate levels of overexpression (observed in the cell 
lines used in these studies) leads to a more aggressive 
form of ovarian cancer. In conclusion, our studies reveal 
that ARID3BFL increases the aggressiveness of ovarian 
tumor formation and decreases survival time in vivo. We 
propose that one mechanism for ARID3B enhancement of 
tumor growth is through activation of genes involved in 
CSC pathways leading to CSC production and paclitaxel 
resistance. 
MATERIALS & METHODS
Immunohistochemistry (IHC) and H&E
Three TMAs containing ovarian cancer sections 
were provided by Dr. Tanja Pejovic (Oregon Health and 
Science University). These TMAs contained section 
from102 different cases. IHC was performed on paraffin 
embedded tumors according to the staining procedure 
provided by the VECTASTAIN ABC KIT using 
ImmPACT DAB and Hematoxylin QS as a counterstain 
(Vector Laboratories, Burlingame, CA). Anti-ARID3B 
IHC Antibody (Bethyl Laboratories, Montgomery, 
TX), anti-KI67 (Novus Biologicals, Littleton, CO), and 
Cleaved PARP (Asp214) (Cell Signaling Technology, 
Danvers, MA) were used. Slides were scanned at the 
20x magnification setting using Aperio Scan Scope 
(Vista, CA). Hematoxylin and eosin (H&E) staining was 
performed on xenograft tumors from SKOV3IP-RFP and 
SKOV3IP-RFP cells injections according to standard 
procedures.
Cell Culture 
SKOV3 cells were obtained from ATCC 
(Manassas, VA, USA) (8/2011) and maintained in 
McCoy’s 5A medium with 0.1mM L-glutamine, 10% 
fetal bovine serum (FBS), 50U/ml penicillin and 50µg/
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ml streptomycin. SKOV3IP cell line (from Dr. Mills, MD 
Anderson Cancer Center), was maintained in RPMI-1640 
medium supplemented with 0.1mM L-glutamine, 5% 
FBS, 50U/ml penicillin and 50µg/ml streptomycin, 1% 
non-essential amino acids, and 1mM Sodium pyruvate 
and Hygromycin B. OVCA429 cells were provided by 
Dr. Bast (MD Anderson Cancer Center) and grown in 
minimal essential media with 0.1mM L-glutamine, 10% 
FBS, 50U/ml penicillin and 50µg/ml streptomycin. Red 
fluorescent protein (RFP), ARID3BFL and ARID3BSH 
were overexpressed using a lentiviral approach as 
described [15]. Antibiotic selection was not used as nearly 
100% of the cells were transduced with the lentivirus. For 
in vivo and in vitro studies, cells were transduced with 
virus, expanded and injected into mice or used for other 
experiments within 2-3 weeks. Tissue culture reagents 
were obtained from Life Technologies, Carlsbad, CA. All 
cell lines were authenticated on October 1, 2013, ATCC 
by STR profiling. 
Western Blot Analysis
Whole cell lysates were prepared using RIPA buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% 
EDTA, 0.1% SDS and protease inhibitors). Bicinchoninic 
Acid (BCA) protein assay (Pierce, Rockford, IL) 
determined protein concentrations. Thirty µg of whole cell 
lysates were separated by SDS-PAGE and transferred to 
nitrocellulose membrane. Membranes were blotted with 
ARID3B antibody (Bethyl Laboratories, Montgomery, 
TX: Cat# A302-564A), and Histone H3 (D1H2) antibody 
(Cell Signaling, Danvers, MA) for loading control. 
Densitometry analysis was performed on three blots using 
BIORAD Chemidoc XRS+ System Image Lab Software 
(Hercules, CA).
Xenograft mouse models of ovarian cancer
Under an approved IACUC protocol (ND #14-060), 
six-week-old female nude mice nu/nu (Charles River, 
Wilmington, MA) were maintained at the Freimann 
Life Science Center (University of Notre Dame). In the 
pilot study (4 mice per group), 2x106 SKOV3IP-RFP, 
SKOV3IP-ARID3BFL, and SKOV3IP-ARID3BSH 
cells in 300 μl of phosphate buffered saline (PBS; 137 
mM NaCl, 2.7 mM KCl, and 11.9 mM phosphate buffer, 
pH 7.4) were injected intraperitoneally (IP) into nude 
mice. Mice had visible tumors after 3 weeks and were 
euthanized. For the survival studies and analysis of tumor 
growth, 1x106 SKOV3IP-RFP (9 mice), SKOV3IP-
ARID3BFL (16 mice), and SKOV3IP-ARID3BSH (14 
mice) cells in 300 μl of PBS cells were each injected into 
nude mice. Two separate experiments were conducted on 
independent transductions of the cells. Mice were imaged 
weekly. When the mice showed signs of illness they were 
imaged twice weekly and then euthanized. Ascites fluid 
was collected using a 25 G needle and 5 mL syringe. If no 
ascites fluid was present a peritoneal wash was performed 
by injecting 2 mL of PBS IP and then collecting the fluid. 
Fluorescent imaging of tumor growth in live animals were 
acquired at the Notre Dame Integrated Imaging Facility 
using the Multispectral FX (Carestream, Rochester, NY 
RNA extraction and qRT-PCR
Gene array (see Supplemental information) and 
qRT-PCR analysis was conducted on tumor derived ascites 
cells from SKOV3IP-RFP and SKOV3IP-ARID3BFL 
injected mice. Ascites cells were collected from the mice 
as described above. Half of the fluid was centrifuged to 
pellet the cells. The supernatant was removed and the cells 
were placed in 0.5 mL of TRIzol (Invitrogen, Carlsbad, 
CA). The remaining ascites fluid was cultured as described 
for SKOV3IP cells. The RNA was extracted using TRIzol 
according to the manufacturer’s recommendations. cDNA 
was prepared using the High Capacity cDNA kit (Life 
Technologies, Carlsbad, CA) . qRT-PCR was performed 
using Taqman master mix solution (Life Technologies, 
Carlsbad, CA) and primers for Col1A1, Col1A2, 
ARID3B, PROM1, LGR5, SFRP1, WISP1, and SNAI2 
from Integrated DNA Technologies (Coralville, IA) and 
GAPDH from (Qiagen, Valencia, CA). qRT-PCR was 
conducted in duplicate using the Biorad CFX96 C1000 
System (Biorad, Hercules, CA). Statistics were calculated 
using a one-way ANOVA.
Flow Cytometry
To examine stem cell markers in SKOV3IP cells 
expressing ARID3BFL or control cells, flow cytometry 
was performed to detect CD133 and CD44 and data were 
analyzed with FlowJo software (Ashland, OR). SKOV3IP, 
SKOV3IP-RFP, and SKOV3IP-ARID3BFL cells were 
incubated with CD133/(AC133)-PE (Miltenyi Biotec, 
Auburn, CA) and anti-human CD44-APC (Biolegend, 
San Diego, CA). N=3. Statistics were calculated using a 
one-way ANOVA. Expression of CD117and CD133 was 
evaluated in SKOV3 CSC and SKOV3 (Control) cells that 
were either non-transduced or stably expressing RFP or 
ARID3B. Cells were harvested with Accumax (Millipore, 
Billerica, MA), and washed twice with cold PBS. Cells 
were incubated in their respective media for 1 h prior to 
labeling. Cells were suspended in 0.1%BSA/PBS and 
labeled with anti-CD 133-PE (Mitenyl Biotec, Auburn, 
CA) and anti-CD117-FITC (anti-CD117-Biotin; Cell 
Signaling, Danvers, MA and Streptavidin-FITC; Mitenyl 
Biotec, Auburn, CA) per the manufacturer’s instructions. 
Cells were fixed overnight in 1% paraformaldehyde. 
Flow cytometry was performed using a Beckman Coulter 
FC500 Flow Cytometer (Brea, CA). N=3 Statistics were 
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calculated using Two-Way Anova test. 
Enrichment for Cancer Stem Cells 
CSC cultures using SKOV3, SKOV3-RFP, and 
SKOV3-ARID3B cells, were generated by treating cells 
with 20μM of cisplatin (Sigma, St. Louis, MO) for 72h. 
Surviving cells were trypsinized and cultured in serum 
free DMEM/F12 media (Life Technologies, Grand Island, 
NY) supplemented 5μg/ml insulin (Invitrogen, Carlsbad, 
USA), 10 ng/ml human recombinant epidermal growth 
factor (EGF; Invitrogen, Carlsbad, USA), 10 ng/ml basic 
fibroblast growth factor (bFGF, Invitrogen, Carlsbad, 
USA), 12 ng/ml leukemia inhibitory factor (LIF; Santa 
Cruz Biotechnologies, Santa Cruz, CA) and 0.4% bovine 
serum albumin (BSA; Sigma, St. Louis, MO). The 
selected cells formed non-adherent spheres when grown 
in this condition. The media was changed every 2 days. 
SKOV3 CSCs were collected for RNA analysis and flow 
cytometry. 
MTT Assay to measure response to paclitaxel 
treatment
Ovarian cancer cells were plated onto 96-well plates 
(5000 cell per well) overnight. Cells were treated with 
increasing concentrations of paclitaxel for 48h. Viable cells 
were assayed using the MTT (3-(4, 5-Dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide) assay according 
to the manufacturer’s instructions (Sigma, St. Louis, 
MO). The plates were read at 595 nm, and the data were 
analyzed using SoftmaxPro Version 3.1.1 (Molecular 
Devices, Sunnyvale, CA). Experiments were performed 
in triplicate and statistics were calculated using a Two-
Way Anova test.
Statistics
All statistical analyses were performed using the 
Prism software (GraphPad Software, Inc., La Jolla, CA). 
The data are presented as the means ± SEM. Comparisons 
between experimental conditions and controls were made 
by one-way ANOVA or Two-Way ANOVA with and 
without repeated measures with either Tukey or Sidak 
posttests. Student t –tests were used in the comparison of 
ARID3B nuclear expression and tumor relapse. Animal 
studies were analyzed using the Kaplan-Meier survival 
analysis with log-rank significance test and correlation 
analysis. Statistical differences are denoted as follows: * 
P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
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